Latest Breaking News On - Institute for global health infectious diseases - Page 3 : vimarsana.com
New Trial Data: Regeneron s Antibody Treatment Prevents COVID Infections
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Regeneron s COVID-19 antibody cocktail protects against infection, says Phase 3 study
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.
Infectious disease doctor Dr. Amesh Adalja on several states see spike in coronavirus cases.
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday. The drug, REGEN-COV, also significantly reduced duration of symptoms and lowered viral levels, Regeneron said.
REGEN-COV, comprised of casirivimab with imdevimab, has already received emergency use authorization from the FDA in the U.S. Under the current EUA, the combo therapy is approved to treat non-hospitalized adults and adolescents with mild to moderate symptoms of COVID-19 and who are at high risk for developing severe symptoms or the need for hospitalization.
Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19
A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention.
Shares0
A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that’s easier for both physicians and patients.
Published: Apr 12, 2021
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration
Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (
vimarsana © 2020. All Rights Reserved.